Despite that, our findings did demonstrate that CHIT1 levels in the CSF represent a promising biomarker for the prognosis of HAM/TSP, particularly to differentiate patients with rapid progression and worse prognosis. The gene discussed is CHIT1; the disease is tropical spastic paraparesis.